Respiratory

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

Respiratory diseases made up the hospitalizations in older adults after they were exposed to wildfire smoke.

Smoking prevalence is projected to decline by 2035, yet health consequences persist due to slower reductions among older adults.

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

Edgardo S. Santos, MD, FACP, FASCO, a hematologist and medical oncologist, discussed how artificial intelligence (AI) is revolutionizing lung cancer care by analyzing imaging data to detect malignancies and interstitial lung disease, while stressing the importance of regulation to ensure its safe and ethical use.

Inhaling wildfire smoke could have immediate effects on children in Los Angeles, such as coughing and wheezing, which may lead to more long-term health effects.

Irina Dralyuk, MD, discusses how to best prevent vulnerable parties, especially children, from breathing in the toxic smoke in Los Angeles.

Both candidates combine 2 already licensed vaccines to prevent influenza and COVID-19.

These data from the Environmental Protection Agency were presented at the Society for Risk Analysis annual meeting.

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory syncytial virus (RSV).

A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on vaccines for flu and respiratory syncytial virus (RSV).

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options for patients with idiopathic pulmonary fibrosis (IPF).

The COVID-19 pandemic required an evolution of traditional nursing practices, but the unpredictability led to increased stress, burnout, and job dissatisfaction.

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF).

Introducing artificial intelligence (AI)–powered robots like AMECA into health care comes with potential benefits like improved clinical decision-making and faster diagnoses, but also presents challenges such as misinformation risks and data privacy concerns.

Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk of mortality from idiopathic pulmonary fibrosis (IPF).

Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.

Speakers at the European Respiratory Society Congress 2024 provided updates to the 2 trials focusing on depemokimab for severe asthma and dupilumab for pediatric asthma.

New findings highlight the potential role of artificial intelligence in supporting health care professionals, but thorough testing is needed before its integration into everyday clinical practice.

Also known as coal workers’ pneumoconiosis, black lung disease (or miner’s lung) is typically the result of inhaling coal dust for many years that causes scarring in the lungs and makes breathing increasingly difficult. The prevalence of black lung has been on the rise in the US.

Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by preventing disease progression.

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast.

While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world settings.